Company intelligence / Profile preview

Novacyt

Ownership: Private
Employees: ~119
Development stage: Other

Overview

Novacyt develops and commercializes in vitro molecular diagnostic tests with a global presence. The company gained prominence during the COVID‑19 pandemic with its rapid SARS-CoV‑2 test. It has expanded into reproductive health, precision medicine genotyping assays, infectious disease panels, and advanced DNA/RNA sample prep technologies. In September 2023 it acquired Yourgene Health to strengthen its portfolio in non-invasive prenatal testing and genomic medicine.

Therapeutic areas: Women's HealthPulmonologyInfectious Diseases
Modalities: DeviceDiagnostic assay (PCR-based)Molecular assayNext-generation sequencing workflow (NGS workflow)Real-time quantitative PCR kit (qPCR kit)DNA sample preparation platform
Industry: Molecular Diagnostics

Partnerships

AstraZenecaGlaxoSmithKlineUniversity of Cambridge

Beyond the preview

Go deeper on Novacyt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novacyt.

Explore the full profile